071 the Impact of Androgen Deprivation Therapy on Compliance with Intracavernous Injections

Androgen deprivation therapy (ADT) for prostate cancer lowers testosterone to castrate levels resulting in loss of sex drive, difficulty achieving orgasm and erectile tissue structural changes. Intracavernous injections (IC) are well recognized as a strategy for treating ED and are used regularly in erectile rehabilitation programs for men after radical prostatectomy and prostate radiation. There is no available literature on the compliance of men on IC who are concomitantly on ADT. Men with ED who had failed maximum dose PDE5 inhibitor agents; were enrolled in our IC program for ≥12 months (m); men treated with radiation therapy (RT) alone were compared to men who had had RT combined with ADT (and were still using ADT). 12 month follow-up or longer was required to be included in the analysis. Demographic, comorbidity, sexual function and sexual activity data were recorded. IC compliance was defined as use of IC ≥1/month and patients were followed at 3 months (m), 6m and 12 months after initial in-office IC training. Multivariable analysis was performed to define predictors of continued use of IC at 12 m after training completion.